Amgen, Inc. (NASDAQ: AMGN) is seeing some positive action this morning. The biotech and drug maker announced Phase 3 trial results evaluating denosumab versus Zometa in advanced cancer patients with solid tumors or multiple myeloma showing that denosumab delayed skeletal related events (osteoporosis etc.). Shares are up over 2% at $62.20 on over 175,000 shares as of 8:52 AM EST. As this is already the leader here, the fallout may be limited in competitors. If you can believe it, Amgen is now within about 3% of its 52-week highs. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment